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Key Clinical Message
Vitamin D-dependent rickets type 1 VDDR-1 is a recessive inherited disorder
with impaired activation of vitamin D, caused by mutations in CYP27B1. We
present long-time follow-up of a case with a novel mutation including high-res-
olution peripheral quantitative computed tomography of the bone. Adequate
treatment resulted in a normalized phenotype.
Keywords
Bone mineral density, CYP27B1, HR-pQCT, Pseudo-vitamin D deficiency
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Introduction
Vitamin D is one of the major hormones regulating blood
levels of calcium and mineral homeostasis of the bone. It
is an inactive prohormone that can be ingested or synthe-
sized in the skin. The production of the active hormone,
calcitriol or 1a,25-dihydroxyvitamin D3 (1,25(OH)2D),
results from sequential hydroxylation by members of the
cytochrome P-450 enzymes [1]. The regulated step is 1-hy-
droxylation (Fig. 1) by 1-a-hydroxylase (1a-OHase), pri-
marily expressed in the kidney [2]. 1,25(OH)2D exerts its
biological function by binding to a nuclear receptor in tar-
get tissues, thereby altering transcription of various vitamin
D-dependent proteins. In short, 1,25(OH)2D facilitates
bone mineralization by promoting osteoblast function and
osteoclast differentiation while maintaining blood calcium
and phosphate levels through enhanced gastrointestinal
and renal absorption [3]. It also regulates its own activity
by up-regulating 24-hydroxylase (which metabolizes 1,25
(OH)2D) and fibroblast growth factor-23 (FGF-23) and
down-regulating parathyroid hormone (PTH) [2,3].
Vitamin D-dependent rickets type 1 (VDDR-1) [4],
also known as pseudovitamin D deficiency rickets
(PDDR)[5] is a rare autosomal recessive disease where
1a-OHase deficiency impedes the activation of vitamin D
(MIM #264700). Symptoms usually present at an age of
6–12 months with growth retardation and irritability, pre-
sumably due to bone pain and muscle weakness. At this
age, clinical rickets is evident with classical symptoms
such as widening of ankles, wrists and costochondral
junctions, frontal bossing, delay in closure of fontanelles,
and eruption of teeth, [6–8]. Laboratory findings include
hypocalcaemia, hypophosphatemia, and elevated serum
alkaline phosphatase and PTH. Patients with VDDR-1
may present with secondary reduced urinary
calcium excretion, aminoaciduria, and hyperchloremic
acidosis [9]. Plasma levels of 25-hydroxyvitamin D
are normal, but levels of 1,25(OH)2D are low or
undetectable [4].
CYP27B1 (MIM #609506), the only gene in which
mutations cause VDDR-1, is located on chromosome
12q13.3 [10]. To date, more than 50 different mutations
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have been reported including missense or nonsense muta-
tions, deletions, splicing mutations, and duplications [11–
14]. The clinical symptoms regress and biochemical find-
ings normalize within months of sufficient treatment with
calcitriol, but the necessary dose varies between individu-
als, which can only in part be explained by molecular
studies of the specific mutations [12,15]. Successful cessa-
tion of vitamin D treatment around puberty has been
reported in a very limited number of cases of VDDR-1
[15–17].
Bone mineral density (BMD) assessed by dual-energy
X-ray absorptiometry (DXA) was markedly reduced (me-
dian z-score 5.2) at diagnosis in five children with
VDDR-1 and normalized within 3 months of treatment
[18]. While DXA measures bone mass, high-resolution
peripheral quantitative computed tomography (HR-
pQCT) measures both bone mass, geometry and microar-
chitecture (Fig. 2). We report a novel mutation causing
VDDR-1, and the clinical and skeletal phenotype assessed
by use of DXA and HR-pQCT.
Clinical report
The male patient was born after an uneventful pregnancy
by spontaneous delivery. The parents are nonconsan-
guineous healthy Caucasians, and the patient has two
elder and one younger healthy siblings. Birth weight and
length were 3430 g and 51 cm, respectively. He was fully
breastfed the first 6 months and partly breastfed until
age 10.5 months. Growth and development milestones
were normal including the ability to sit at 6 months,
crawl, and stand up at 8 months. At the age of
8 months, growth and weight stagnated, and he lost the
ability to crawl and stand. There was no history of sei-
zures. The first clinical examination at 18 months
revealed height 3 SD and weight 3.5 SD. Craniofacial
features were not clearly dysmorphic, but a triangular
mouth and low ears were noted. Musculoskeletal exami-
nation showed a generally atrophic body with muscle
weakness and reduced subcutaneous fat, and signs of
rickets with rachitic rosary, lack of tooth eruption, pal-
pable widening of distal radius, and double malleoli. Bio-
chemical tests (normal intervals in parenthesis) showed
markedly decreased ionized serum calcium 1.08 mmol/L
(1.20–1.35 mmol/L), serum phosphate 0.72 mmol/L
(1.20–1.80 mmol/L) and 1,25(OH)2D 24 pmol/L (adults
71–177pmol/L), normal serum chloride 107 mmol/L
(102–112 mmol/L) and increased serum alkaline phos-
phatase 14020U/L (55–515U/L), PTH 57.0 pmol/L (1.1–
6.9 pmol/L), and serum 25-(OH)D 96 nmol/L (adults:
37–120 pmol/L with supplements and 10–66 without).
Twenty-four-hour urine showed signs of phosphate wast-
ing with tubular reabsorption of 65% (normally above
80%), low calcium excretion, ketoaciduria, and hyper-
aminoaciduria. There was a tendency toward metabolic
acidosis with negative base excess of 5. According to
the medical record, radiologic findings included general
rough halisteresis of all bones with severe cupping of
metaphyses, poorly defined bone nuclei, and subpe-
riosteal bleedings. There were fractures of both ulna and
tibia with visible fracture lines and callus. Chest X-ray
was described with rachitic rosary, and otherwise normal
heart and lung findings.
On suspicion of hereditary hypophosphatemic rickets,
treatment was initiated with vitamin D, calcium, and
phosphate supplements, and later changed to alfacalcidol,
as the diagnosis was corrected to VDDR-1. Within
5 months of treatment, 0.5 lg alfacalcidol daily sufficed
to hold blood samples within normal ranges. Normal
growth and development resumed, and normal bone age
was reached at 9 years of age. Treatment was adjusted
Figure 1. Regulation of Vitamin D hydroxylation. Vitamin D is
sequentially hydroxylated by hepatic 25-OHase (CYP2R1) and renal
1a-OHase (CYP27B1) rendering the active hormone 1,25(OH)2D. 1-
hydroxylation is the rate limiting and regulated step. 1a-OHase is
stimulated by parathyroid hormone (PTH) and inhibited by FGF-23 and
by itself.
Figure 2. HR-pQCT scans of distal radius and tibia of patient with
VDDR-1.
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according to the levels of serum calcium and phosphate,
PTH, and urinary calcium/creatinine ratio. Minor
nephrocalcinosis was observed on ultrasound, but renal
function remained normal. On average, daily doses of
alfacalcidol varied between 0.36 and 1.29 lg, showing a
tendency toward higher doses with increasing age.
At 18 years of age, the patient reported neither symp-
toms of rickets nor fractures after initiation of treatment.
He reported having experienced bone pain and general
malaise after a few days without medication. Physical
examination revealed a height of 167.6 cm, corresponding
to the expected height estimated from his parents, and
weight of 58.4 kg. A prominent sternoclavicular joint and
upper costosternal joints on the right side were observed.
Chest X-ray showed no visible pathology (Fig. S1). Blood
samples were within normal ranges and renal ultrasound
was without nephrocalcinosis.
DXA showed Z-scores of 1.0 and +1.3 in the lumbar
spine (L1-4) and total hip, respectively. HR-pQCT
(Table 1 and Fig. 2) showed overall values for bone min-
eral density (BMD), trabecular and cortical BMD, trabec-
ular number, thickness and spacing, and cortical thickness
comparable to a cohort of 64 Danish males aged 20-29
[19], and was thus considered normal.
Materials and methods
DNA Sequencing
To identify the genetic mutations causing VDDR-1, geno-
mic DNA was isolated from peripheral blood leucocytes
of the patient and his parents after obtaining written
informed consent. All exons and exon-intron boundaries
of CYP27B1 (RefSeq: NM_000785.3) were analyzed by
bidirectional sequencing using the BigDye Terminator
v.3.1 cycle sequencing kit (Applied Biosystems, Foster
City, CA, USA) and an ABI3730XL capillary sequencer
(Applied Biosystems).
Mutation prediction
We used the prediction programs PolyPhen-2, Muta-
tionassessor, Mutationtaster, and SIFT to assess the effect
of amino acid substitution for p.Arg432Ser, which had
not been previously described. Clustal W (MegAlign;
DNA STAR, Madison, WI, USA)) was used to test the
evolutionary conservation of the substituted amino acid
by alignment.
Results and Discussion
Direct sequencing of CYP27B1 revealed two missense
mutations. The exon 7, c.1166 G>A, p.Arg389His
(CGT>CAT) mutation was inherited from the mother
and has previously been identified as disease causing
[15,17,20,21]. The second mutation, exon 8, c.1294 C>A
p.Arg432Ser (CGC>AGC), has, to the best of our knowl-
edge, not previously been described (Fig. S2). The latter
mutation was not identified among the parents and may
be a “de novo” mutation or due to gonadal mosaicism. A
mutation located in the same codon c.1294 C>T
p.Arg432Cys (CGC>TGC) was evaluated by Cui et al.
[12] who performed site-directed mutagenesis and
compared 1a-OHase activity of mutant to WT enzyme in
Table 1. HR-pQCT results from the patient compared to a group of 64 Danish men aged 20-35 years examined on the same machine as Hansen
et al. [19].
Radius Tibia
Subject Control group Subject Control group
Result (SD from median) Mean  SD Result (SD from median) Mean  SD
Total area (mm2) 292.7 (1.1) 358  61 734.2 (1.1) 898  144
Cortical area (mm2) 54.7 (1.7) 75  12 159.5 (0.0) 160  32
Trabecular area (mm2) 233 (0.7) 278  62 575.6 (1.1) 737  152
Total BMD (mg/cm3) 330.3 (0.4) 354  53 368 (+0.5) 339  54
Cortical BMD (mg/cm3) 776.7 (2.3) 873  42 862.1 (0.4) 876  37
Trabecular BMD (mg/cm3) 215.6 (+0.5) 199  33 232 (+0.5) 218  30
Trabecular BV/TV (%) 18 (+0.5) 16.5  2.8 19.3 (+0.5) 18.1  2.48
Trabecular number (1/mm) 2.44 (+1.7) 2.06  0.22 2.36 (+0.6) 2.20  0.26
Trabecular thickness (mm) 0.074 (0.5) 0.080  0.013 0.082 (0.1) 0.083  0.010
Trabecular spacing (mm) 0.336 0.406 [0.367–0.449]a 0.342 0.362 [0.341–0.418]a
1/SD Tb.N (mm) 0.119 0.163 [0.148–0.182]a 0.135 0.153 [0.139–0.181]a
Cortical thickness (mm) 0.78 (1.4) 1.02  0.17 1.51 (+0.8) 1.31  0.25
aMedian [p25–p75].
BMD, bone mineral density; SD, standard deviation; Tb.N, trabecular number.
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cell culture. They found a reduced activity to 6.9% of the
WT enzyme.
The variant p.Arg432Ser was evaluated using the pre-
diction softwares Polyphen2, SIFT, Mutationassessor, and
Mutationtaster. All except SIFT predicted the substitution
to be pathogenic. Homology analysis of p.Arg432Ser in
different species found the residue to be highly conserved
(Fig. 3).
Albeit having only about 20% sequence homology,
CYP enzymes in both prokaryotes, and eukaryotes retain
a remarkable conservation in secondary and tertiary struc-
ture [22], and thus it was possible to produce a 3D model
of CYP27B1 on the basis of the crystal structure of rabbit
CYP2C5 [23], which may be used to predict the func-
tional consequences of mutated residues responsible for
VDDR-1. The amino acid R432 in CYP27B1 was deter-
mined to be part of a highly conserved triad of Glutamic
Acid-Arginine-Arginine, the ERR-motif. Although the
position of these amino acids in primary structure varies
widely in different CYP enzymes, they form salt bridges
and thus a highly conserved tertiary structure close to the
heme-binding region. The motif was already proposed to
be essential for core folding and heme stabilization by
hydrogen binding with the meander region of all CYP
enzymes in the first comparative studies of CYP crystal
structures in 1995 and disruption of the motif renders the
enzymes inactive [22]. It is thus tempting to speculate
that exchange of a positively charged amino acid capable
of forming salt bridges such as Arginine with an
uncharged amino acid such as Serine (or Cystein [12])
may be detrimental. In 1999, a role of the ERR-motif in
redox partner interaction has also been proposed [24].
Our results on BMD, measured by DXA confirmed ear-
lier findings of a normal bone phenotype in well-treated
patients with VDDR-1 [18]. In addition, the HR-pQCT
showed normal geometry, bone volumetric density, and
microarchitecture. These observations are probably
explained by treatment with alfacalcidol and close moni-
toring, resulting in near-normal values of electrolytes and
PTH.
In the present case study, we identified a novel CYP27B1
mutation in exon 8 c.1294 C>A p.Arg432Ser (CGC>AGC)
in a patient with clinical and biochemical manifest VDDR-
1. The typical VDDR-1 phenotype of the untreated
patient, as well as the documented VDDR-1 in an unre-
lated patient with a mutation in the same codon and the
position of the mutation in an essential part of the
enzyme, strongly suggests that this mutation is pathogenic.
Results from homology analysis and prediction software
also support this hypothesis. Definite experimental proof
would require site-directed mutagenesis and functional
analysis of mutant 1a-OHase protein.
Although long-term follow-up data on aged VDDR-1
patient is awaited, no skeletal abnormalities or increased
fracture risk have been reported in well-treated patients.
The normal bone microarchitecture and geometry in our
adult patient supports that well-treated subjects may have
normal bone morphology. In conclusion, we present a
case study of a patient with a novel CYP27B1 mutation
and the follow-up after 18 years with adequate medical
treatment. The skeletal phenotype was normalized and
there were no clinical symptoms.
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Additional Supporting Information may be found in the
online version of this article:
Figure S1. Radiographs. A. Posterior-anterior chest X-ray
at age 18 years, described as normal. B. Left hand at age
14 years, described as normal bone age. C. Left clavicula
at 18 years D. Right clavicula at 18 years.
Figure S2. Direct sequencing revealed the heterozygous
mutation c.1166G>A, p.Arg389His inherited by the
mother a presumable de novo mutation c.1294C>A;
p.Arg432Ser.
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